Aedes Aegypti mosquito: the vector behind dengue, yellow fever, and other diseases
18 Jun 2024
Written by Maya Cherian, Public Health Medical Officer
Reviewed by Dr Nick Walsh MD PhD(epi) BScMed(hons) MPH FAFPHM FAChAM
The Aedes Agypti (A. aegypti) mosquito can be found in tropical and subtropical areas worldwide. The A. Aegypti mosquito is a small, dark mosquito that can be identified by the white bands on its legs and a silver-white pattern of scales on its body. The mosquito has been compared to the Greek musical instrument, the lyre (Figure 1).1
Figure 1: Lyre
The mosquito has been compared to the
Greek musical instrument, the lyre.
The A. Agypti don’t travel long distances, moving only a few blocks and have a total life span of approximately three weeks.
The A. Aegypti mosquito has historically been found in tropical and subtropical areas in forested areas. Over time geographic spread has increased to include Europe, the Southern Cone of South American and the United States.3 With urbanisation, the mosquito can survive in a wide range of artificial containers, adapting to both indoor and outdoor aquatic container habitats.
Disease transmission
The A. Aegypti mosquito is the vector for dengue, yellow fever, chikungunya and Zika virus (Table 1).4 It has been identified as a potential vector for Venezuelan equine encephalitis virus and studies have shown it is capable of transmitting West Nile virus.4
Summary of diseases transmitted by Aedes Aegypti mosquito
Dengue
Virus
Genus: Flavivirus.
Epidemiology
DENV is endemic in the tropics and subtropics. Dengue cases have significantly increased globally. Since January 2024, there have been over 5 million reported cases and over 2000 deaths globally.5 Asia represents 70% of the global disease burden.
Clinical presentation
Dengue is commonly referred to as break bone fever, due to the fever and muscle and joint pain associated with infection. Presentations are characterised by three phases, febrile, critical and convalescent phase.
Treatment
No treatment currently available.
Prevention
Avoid mosquito bites.
Dengvaxia®6is currently the only available vaccine in the world, available for the prevention of secondary dengue.
Yellow fever
Virus
Genus: Flavivirus.
Epidemiology
Sub-Saharan Africa and tropical South America.
As of 25 Feb 2024, 13 countries in World Health Organization (WHO) African region have probable and confirmed cases
Clinical presentation
Asymptomatic
Common symptoms: fever, muscle pain with prominent back pain, headache, loss of appetite, nausea or vomiting.
Few cases (~12%)8 progress to systemic infection leading to acute liver and kidney failure.
Treatment
No treatment currently available.
Prevention
Vaccine preventable.
Single vaccine provides life-long immunity within 10 days (80-100%) and within 30 days (99%).7
Avoid mosquito bites.
Chikungunya
Virus
Family: Togaviridae,
Genus: Alphavirus.
Epidemiology
Occurs in tropical and subtropical regions.
Cases involve large outbreaks with high attack rates, affecting up to 75% of the population where virus is circulating.
Outbreaks occur during topical rainy season.
Clinical presentation
Up to 28% of cases remain asymptomatic.
Clinical symptoms include fever lasting up to 1 week and joint pain, most commonly occurring in the hands and feet. Other symptoms include headache, conjunctivitis, myalgia, nausea, vomiting or rash.
Serious complications includes hepatitis, myocarditis, neurological disease, ocular disease, renal disease and severe skin lesions.
Treatment
No treatment currently available.
Prevention
IXCHIQ approved by US FDA10 for individuals under 18 years old at increased risk of exposure to chikungunya virus.
Avoid mosquito bites.
Not approved for use in Australia.
Zika virus
Virus
Family: Flaviviridae,
Genus Flavivirus.
Epidemiology
Tropical and subtropical regions.
Since 2007, outbreaks have occurred throughout the Pacific Islands and Southeast Asia.
In 2015, there was a large outbreak throughout the Americas.
Clinical presentation
Asymptomatic or mild.
Symptoms include fever, arthralgia, non-purulent conjunctivitis and maculopapular rash.
Hospitalisation and death are uncommon.
Vertical transmission can lead to congenital Zika virus infection, leading to microcephaly with brain anomalies and foetal loss.
Treatment
No treatment currently available.
Prevention
No vaccine or preventable medication currently available.
Avoid mosquito bites.
Climate change and the Aedes Aegypti mosquito
There have been ongoing concerns for many years on the effects of climate change on mosquito populations. Without reductions in greenhouses gases, temperatures will continue to rise, favouring the development of new mosquito development.12 The prevalence of vector-borne diseases has increased with malaria, dengue, lyme disease and West Nile virus infection expected to further rise if appropriate control strategies are not implemented.13 Surveillance and control form the basis of community and household or individual adaptation strategies to respond to vector-borne diseases with adaptation measures required to decrease the impact of such diseases.13
Novel methods for decreasing transmission
The World Mosquito Program (WMP) is a not-for-profit group14 led by Monash University. The WMP is leading research into preventing the transmission of vector-borne diseases using Wolbachia. Wolbachia is an intracellular bacterium safe for humans and the environment that naturally occurs in 50% of arthopod (including insects) species. Its presence upregulates host immune mechanisms, resulting in an ‘antiviral’ effect. A. Aegypti does not normally carry Wolbachia; however, other mosquitoes do. Wolbachia blocks the growth of viruses such as dengue, yellow fever, chikungunya, and Zika in A. Aegypti mosquitoes. Wolbachia mosquitoes have been released at a number of sites in northern Australia over the past decade and more recently overseas, resulting in the replacement of the mosquito population and a decreased dengue incidence by 77% and dengue hospitalisation by 86%. Food chains or population size are not decreased by Wolbachia.
References
- Dengue Transmission | Nature.com
- Life Cycle of Aedes aegypti and Ae. albopictus Mosquitoes | US CDC
- Climate change and viral emergence: evidence from Aedes-borne arboviruses
- Aedes Aegypti | ECDC
- Dengue worldwide overview | ECDC
- Advice on the use of dengvaxia for Australians | ATAGI
- Yellow fever | African Region
- Yellow Fever | CDC Yellow Book 2024
- Chikungunya | CDC Yellow Book 2024
- FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus | FDA
- Zika | CDC Yellow Book 2024
- Accelerating invasion potential of disease vector Aedes aegypti under climate change | Nature Communications
- Climate Change and Vectorborne Diseases | New England Journal of Medicine (nejm.org)
- World Mosquito Program
- Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue | New England Journal of Medicine
Dr Maya Cherian
Public Health Physician